Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing.

ABSTRACT:

Background

Closing mucosal defects to reach mucosal healing is an important goal of therapy in inflammatory bowel disease (IBD). Among other cells, monocyte-derived macrophages are centrally involved in such intestinal wound healing. We had previously demonstrated that the anti-α4β7 integrin antibody vedolizumab blocks the recruitment of non-classical monocytes as biased progenitors of wound healing macrophages to the gut and delays wound healing. However, although important for the interpretation of disappointing results in recent phase III trials in IBD, the effects of the anti-β7 antibody etrolizumab on wound healing are unclear so far.

Methods

We analyzed the expression of etrolizumab targets on human and mouse monocyte subsets by flow cytometry and assessed their functi

SUBMITTER: Sommer K 

PROVIDER: S-EPMC10082567 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature